Association of disease characteristics with FDG uptakea in the 34 patients with RA.
| β (95% CI), P | |||||
|---|---|---|---|---|---|
| wj25SUV | wj50SUV | wj75SUV | wjMaxSUV | SJC | |
| Disease duration, yrs | 0.44 (−0.02 to 0.89), 0.06 | 0.45 (−0.02 to 0.92), 0.06 | 0.46 (−0.01 to 0.93), 0.06 | 0.46 (−0.02 to 0.94), 0.06 | 0.05 (−0.09 to 0.18), 0.47 |
| RF | 5.3 (−3.2 to 13.7), 0.21 | 5.3 (−3.5 to 14.1), 0.23 | 5.3 (−3.6 to 14.2), 0.23 | 5.4 (−3.5 to 14.3), 0.23 | 0.92 (−2.52 to 4.35), 0.59 |
| logCRP, mg/dL | −0.06 (−0.26 to 0.14), 0.54 | −0.07 (−0.37 to 0.24), 0.65 | −0.10 (−0.50 to 0.31), 0.63 | −0.11 (−0.60 to 0.37), 0.63 | −0.17 (−1.69 to 1.36), 0.83 |
| ACPA | −1.1 (−10.8 to 8.7), 0.82 | −1.5 (−11.6 to 8.6), 0.77 | −1.6 (−11.7 to 8.6), 0.76 | −1.5 (−11.8 to 8.7), 0.76 | −3.56 (−7.10 to −0.02), 0.049 |
| DAS28 | 2.6 (−1.2 to 6.4), 0.17 | 2.4 (−1.5 to 6.4), 0.21 | 2.4 (−1.5 to 6.4), 0.22 | 2.5 (−1.5 to 6.5), 0.21 | 3.18 (2.08 to 4.27), < 0.001 |
| CDAI | 0.32 (−0.02 to 0.66), 0.07 | 0.30 (−0.05 to 0.66), 0.09 | 0.30 (−0.05 to 0.67), 0.09 | 0.31 (−0.05 to 0.7), 0.09 | 0.37 (0.31 to 0.43), < 0.001 |
| SDAI | 0.34 (0.03 to 0.65), 0.04 | 0.32 (0.00 to 0.65), 0.05 | 0.33 (−0.01 to 0.66), 0.53 | 0.33 (0.00 to 0.66), 0.05 | 0.31 (0.23 to 0.39), < 0.001 |
| TJC28 | 0.40 (−0.46 to 1.26), 0.35 | 0.36 (−0.54 to 1.25), 0.42 | 0.36 (−0.55 to 1.26), 0.42 | 0.37 (−0.54 to 1.28), 0.41 | 0.66 (0.41 to 0.90), < 0.001 |
| SJC28 | 0.94 (0.15 to 1.74), 0.02 | 0.93 (0.11 to 1.76), 0.03 | 0.95 (0.11 to 1.78), 0.03 | 0.96 (0.12 to 1.80), 0.03 | – |
| HAQ | 0.25 (−6.75 to 7.25), 0.94 | 0.30 (−6.91 to 7.50), 0.93 | 0.28 (−7.02 to 7.57), 0.94 | 0.24 (−7.10 to 7.59), 0.95 | 0.43 (−2.11 to 2.96), 0.73 |
| NSAIDs | −5.4 (−15.8 to 4.9), 0.29 | −5.4 (−16.1 to 5.2), 0.30 | −5.5 (−16.3 to 5.3), 0.30 | −5.5 (−16.4 to 5.4), 0.30 | −3.48 (−7.55 to 0.60), 0.09 |
| Prednisone | 2.0 (−8.6 to 12.6), 0.70 | 1.8 (−9.1 to 12.8), 0.73 | 1.8 (−9.2 to 12.9), 0.73 | 1.8 (−9.3 to 13.0), 0.74 | 1.25 (−2.85 to 5.35), 0.54 |
| Methotrexate | −1.1 (−13.1 to 11.0), 0.86 | −1.0 (−13.5 to 11.5), 0.87 | −1.1 (−13.7 to 11.6), 0.86 | −1.1 (−13.8 to 11.6), 0.86 | −2.95 (−7.43 to 1.53), 0.19 |
| Biologic therapy | 6.1 (−2.5 to 14.7), 0.16 | 6.6 (−2.3 to 15.5), 0.14 | 6.8 (−2.3 to 15.8), 0.14 | 6.9 (−2.2 to 15.9), 0.13 | 0.25 (−3.34 to 3.84), 0.89 |
| Anti-TNF therapy | 8.8 (−1.3 to 19.0), 0.09 | 9.1 (−1.4 to 19.7), 0.09 | 9.3 (−1.4 to 19.9), 0.09 | 9.4 (−1.2 to 20.1), 0.08 | −1.19 (−5.41 to 3.03), 0.57 |
Values in bold are statistically significant.
↵a Weighted joint volume SUVs (wjSUV) representing 25%, 50%, 75%, and maximum (100%) uptake (wj25SUV, wj50SUV, wj75SUV, and wjMaxSUV, respectively). ACPA: anticitrullinated protein antibody; DAS28: Disease Activity Score in 28 joints; CDAI: Clinical Disease Activity Index; NSAID: nonsteroidal antiinflammatory drug; HAQ: Health Assessment Questionnaire; RA: rheumatoid arthritis; RF: rheumatoid factor; SDAI: Simplified Disease Activity Index; SJC28: 28-joint swollen joint count; TJC28: 28-joint tender joint count; TNF: tumor necrosis factor.